TWD 65.0
(-1.07%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 827.3 Million TWD | -1.4% |
2022 | 839.03 Million TWD | 13.9% |
2021 | 736.62 Million TWD | -6.96% |
2020 | 791.72 Million TWD | 5.76% |
2019 | 748.6 Million TWD | 6.64% |
2018 | 701.98 Million TWD | 36.56% |
2017 | 514.05 Million TWD | -21.88% |
2016 | 657.99 Million TWD | -26.34% |
2015 | 893.25 Million TWD | 24.05% |
2014 | 720.05 Million TWD | 16.33% |
2013 | 618.96 Million TWD | 39.24% |
2012 | 444.53 Million TWD | -19.78% |
2011 | 554.13 Million TWD | -12.74% |
2010 | 635.06 Million TWD | 21.14% |
2009 | 524.21 Million TWD | 338.3% |
2008 | 119.6 Million TWD | 0.0% |
2006 | 470.66 Million TWD | -34.83% |
2005 | 722.22 Million TWD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 334.09 Million TWD | 24.88% |
2024 Q1 | 267.54 Million TWD | 27.91% |
2023 Q4 | 209.17 Million TWD | -13.54% |
2023 FY | 827.3 Million TWD | -1.4% |
2023 Q1 | 172.4 Million TWD | 102.24% |
2023 Q2 | 203.79 Million TWD | 18.21% |
2023 Q3 | 241.93 Million TWD | 18.71% |
2022 Q3 | 254.95 Million TWD | -7.0% |
2022 FY | 839.03 Million TWD | 13.9% |
2022 Q1 | 224.7 Million TWD | 7.4% |
2022 Q2 | 274.12 Million TWD | 21.99% |
2022 Q4 | 85.24 Million TWD | -66.56% |
2021 Q2 | 187.74 Million TWD | 13.27% |
2021 Q3 | 173.89 Million TWD | -7.38% |
2021 FY | 736.62 Million TWD | -6.96% |
2021 Q4 | 209.23 Million TWD | 20.32% |
2021 Q1 | 165.75 Million TWD | -14.45% |
2020 Q2 | 169.51 Million TWD | -33.39% |
2020 Q4 | 193.75 Million TWD | 11.39% |
2020 Q3 | 173.94 Million TWD | 2.62% |
2020 Q1 | 254.5 Million TWD | 5.62% |
2020 FY | 791.72 Million TWD | 5.76% |
2019 Q2 | 205.03 Million TWD | 22.45% |
2019 Q4 | 240.95 Million TWD | 78.26% |
2019 FY | 748.6 Million TWD | 6.64% |
2019 Q1 | 167.44 Million TWD | -1.64% |
2019 Q3 | 135.16 Million TWD | -34.08% |
2018 Q2 | 178.51 Million TWD | 5.62% |
2018 FY | 701.98 Million TWD | 36.56% |
2018 Q3 | 184.2 Million TWD | 3.19% |
2018 Q1 | 169.01 Million TWD | 53.02% |
2018 Q4 | 170.24 Million TWD | -7.58% |
2017 Q1 | 166.89 Million TWD | 60.93% |
2017 Q2 | 134.08 Million TWD | -19.66% |
2017 Q4 | 110.45 Million TWD | 7.63% |
2017 FY | 514.05 Million TWD | -21.88% |
2017 Q3 | 102.62 Million TWD | -23.46% |
2016 Q1 | 141.91 Million TWD | -53.87% |
2016 Q4 | 103.7 Million TWD | 3.89% |
2016 Q3 | 99.82 Million TWD | -68.06% |
2016 FY | 657.99 Million TWD | -26.34% |
2016 Q2 | 312.53 Million TWD | 120.22% |
2015 FY | 893.25 Million TWD | 24.05% |
2015 Q1 | 196.9 Million TWD | 23.36% |
2015 Q2 | 168.11 Million TWD | -14.62% |
2015 Q3 | 220.56 Million TWD | 31.2% |
2015 Q4 | 307.67 Million TWD | 39.5% |
2014 Q3 | 194.18 Million TWD | 4.56% |
2014 Q2 | 185.7 Million TWD | 2.86% |
2014 FY | 720.05 Million TWD | 16.33% |
2014 Q4 | 159.62 Million TWD | -17.8% |
2014 Q1 | 180.54 Million TWD | -10.96% |
2013 FY | 618.96 Million TWD | 39.24% |
2013 Q1 | 141.63 Million TWD | 31.31% |
2013 Q3 | 138.37 Million TWD | 1.59% |
2013 Q2 | 136.2 Million TWD | -3.83% |
2013 Q4 | 202.75 Million TWD | 46.53% |
2012 Q2 | 144.56 Million TWD | 30.48% |
2012 FY | 444.53 Million TWD | -19.78% |
2012 Q1 | 110.79 Million TWD | -30.43% |
2012 Q4 | 107.86 Million TWD | 48.76% |
2012 Q3 | 72.5 Million TWD | -49.84% |
2011 Q3 | 99.64 Million TWD | -30.31% |
2011 Q2 | 142.99 Million TWD | -6.06% |
2011 Q1 | 152.22 Million TWD | -76.03% |
2011 FY | 554.13 Million TWD | -12.74% |
2011 Q4 | 159.26 Million TWD | 59.83% |
2010 Q2 | - TWD | 0.0% |
2010 FY | 635.06 Million TWD | 21.14% |
2010 Q4 | 635.06 Million TWD | 0.0% |
2010 Q1 | - TWD | 0.0% |
2010 Q3 | - TWD | 0.0% |
2009 FY | 524.21 Million TWD | 338.3% |
2008 FY | 119.6 Million TWD | 0.0% |
2006 FY | 470.66 Million TWD | -34.83% |
2005 FY | 722.22 Million TWD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Grape King Bio Ltd | 1.45 Billion TWD | 43.052% |
Standard Chem & Pharm CO., LTD. | 834.88 Million TWD | 0.908% |
Maywufa Company Ltd. | 169.09 Million TWD | -389.245% |
ScinoPharm Taiwan, Ltd. | 287.05 Million TWD | -188.203% |
Lotus Pharmaceutical Co., Ltd. | 4.1 Billion TWD | 79.85% |
LIWANLI Innovation Co., Ltd. | 5.1 Million TWD | -16112.111% |
PhytoHealth Corporation | -47.11 Million TWD | 1855.85% |
SCI Pharmtech, Inc. | 294.72 Million TWD | -180.708% |
Formosa Laboratories, Inc. | 126.24 Million TWD | -555.327% |
PharmaEssentia Corporation | -623.83 Million TWD | 232.616% |
Bora Pharmaceuticals Co., LTD. | 3.03 Billion TWD | 72.698% |